The Thicket Defined: What You’re Actually Fighting A biologic patent thicket is not a portfolio. It is a deliberate system […]

Executive Summary The pharmaceutical industry runs on a contradiction that has defined the last 25 years. The science has never

1. Why Patent Database Literacy Is a Competitive Asset Patent information does not merely describe a drug’s legal status. It

Drug repurposing has moved well past the era of accidental bedside observations. Today, systematic computational platforms screen millions of compound-indication

Who actually controls what a drug costs at the pharmacy counter? It is not the manufacturer who sets the list

Executive Summary Pharmaceutical procurement costs at the average U.S. hospital nearly doubled between 2014 and 2021, climbing from $10.21 million

The difference between a licensing deal that captures peak asset value and one that leaves money on the table often

1. The Economics of Pharmaceutical Portfolio Failure Why Portfolio Optimization Is Not Optional Pharmaceutical R&D is among the most capital-intensive

Part I: The Strategic Logic of Patent Due Diligence Why Pharma IP Is the Business, Not Just an Asset In